EC Number   |
Application |
Reference |
|---|
   3.5.4.37 | drug development |
ADAR1 is a potential therapeutic target in a subset of cancers |
757778 |
| 3.5.4.37 | drug development |
the enzyme (ADAR1) promotes the Zika virus replication by inhibiting the activation of protein kinase PKR. The enzyme can be a potential target of antiviral drugs |
757225 |
| 3.5.4.37 | medicine |
ADAR2 is a promising target for an anti-tumoral strategy, since ADAR2 alone can simultaneously modulate more than one miRNA and cellular pathway altered in cancer cells |
756885 |
| 3.5.4.37 | medicine |
enzyme (ADAR1) expression is an independent predictor of tumor recurrence. Small molecule inhibition of focal adhesion kinase activity may be a potential therapeutic strategy for the treatment of lung adenocarcinoma with high ADAR1 expression |
758458 |
| 3.5.4.37 | medicine |
the levels of RNA editing by ADAR1 can serve as new tools for diagnosis in cancer stem cell-related illnesses. In situations where ADAR1 overexpression contributes to disease progression, as in several cancers, or where ADAR1 interacts with other proteins in editing-independent manners, inhibition of ADAR1 could potentially be another strategy in treatment |
756867 |
